



**ESOU17**

14th Meeting of the EAU Section of  
Oncological Urology

20-22 January 2017, Barcelona, Spain

[www.esou17.org](http://www.esou17.org)

**esou**

**EAU**  
European  
Association  
of Urology

## Scientific Programme

### Friday, 20 January 2017

- 08.30 - 08.40** **Welcome**  
M. Brausi, Modena (IT)  
P. Gontero, Turin (IT)  
J. Palou, Barcelona (ES)
- 08.40 - 09.00** **Opening address**  
Epigenetics in urogenital cancer  
M. Esteller, Barcelona (ES)
- 09.00 - 13.15** **Prostate cancer I: Diagnosis, pathology and active surveillance**  
Chairs: M. Brausi, Modena (IT)  
A. Heidenreich, Cologne (DE)
- 09.00 - 10.00** **What is an acceptable standard for prostate biopsy in 2017?**
- 09.00 - 09.15** **How to get the best information from a non MRI guided prostate biopsy**  
B. Djavan, Vienna (AT)
- 09.15 - 09.30** **Selecting patients for biopsy in the era of MRI**  
J. Barentsz, Nijmegen (NL)
- 09.30 - 09.45** **Targeted MRI prostate biopsy: Relevant drawbacks**  
A. Briganti, Milan (IT)
- 09.45 - 10.00** **Discussion**
- 10.00 - 10.15** **Role of genomic markers in the diagnostic pathway and prognosis of prostate cancer: Ready for prime?**  
C. Evans, Sacramento (US)
- 10.15 - 10.20** **Discussion**
- 10.20 - 10.35** **A new prostate cancer grading system: A validated alternative to the Gleason Score: Is there a consensus among pathologists?**  
F. Algaba, Barcelona (ES)
- 10.35 - 10.40** **Discussion**
- 10.40 - 10.55** **How to avoid significant cancers when considering active surveillance**  
J. Hugosson, Gothenburg (SE)
- 10.55 - 11.00** **Discussion**

**11.00 – 11.20 Refreshment break**

**11.20 – 12.30 DEBATE: Conservative treatments for intermediate risk patients: Which alternatives?**  
Chairs: J. Hugosson, Gothenburg (SE)  
H. Huland, Hamburg (DE)

**11.20 – 11.35 Active surveillance: Which protocol?**  
A. Alberts, Rotterdam (NL)

**11.35 – 11.50 Focal therapy (Video)**  
S. Crouzet, Lyon (FR)

**11.50 – 12.05 Partial radical prostatectomy (Video)**  
A. Villers, Lille (FR)

**12.05 – 12.20 Novel radiotherapy approaches**  
A. Bossi, Villejuif (FR)

**12.20 – 12.30 Discussion**

**12.30 – 13.05 Active treatment of low risk prostate cancer**

**12.30 – 12.40 Definition of low and very low risk PCa in 2017**  
M. Sedelaar, Nijmegen (NL)

**12.40 – 13.05 DEBATE: In low-risk patients radical prostatectomy, even minimally invasive, should be abandoned**

**12.40 – 12.50 Pro**  
A. Heidenreich, Cologne (DE)

**12.50 – 13.00 Con**  
H. Huland, Hamburg (DE)

**13.00 – 13.05 Discussion**

**13.05 – 14.00 Lunch**

**14.00 – 17.45 Renal cancer I: Localised**  
Chairs: E. Linares, Madrid (ES)  
P. Mulders, Nijmegen (NL)

**14.00 – 14.15 Novel imaging modalities for the solid renal mass**  
J. Walz, Marseille (FR)

**14.15 – 14.20 Discussion**

**14.20 – 14.35 ESUR Lecture: Prognostic and predictive biomarkers and tumour heterogeneity in renal cell carcinoma**  
K. Junker, Homburg (DE)

**14.35 – 14.40 Discussion**

**14.40 – 15.15 DEBATE: Renal biopsy for small renal masses: Always?**

- 14.40 – 14.50 **Yes**  
A. Volpe, Novara (IT)
- 14.50 – 15.00 **No**  
H. Langenhuijsen, Nijmegen (NL)
- 15.00 – 15.15 **Questions and clinical cases to debaters**
- 15.15 – 16.15 **Renal surgery**  
Chairs: E. Liatsikos, Patras (GR)  
A. Mottrie, Aalst (BE)
- 15.15 – 15.30 **New anatomical considerations in planning renal surgery**  
V. Ficarra, Udine (IT)
- 15.30 – 15.35 **Discussion**
- 15.35 – 16.05 **DEBATE: The importance of ischemia vs volume of parenchyma during partial nephrectomy**
- 15.35 – 15.50 **Ischemia (Video)**  
G. Janetschek, Vienna (AT)
- 15.50 – 16.05 **Volume of preserved parenchyma (Video)**  
A. Minervini, Florence (IT)
- 16.05 – 16.15 **Questions and clinical cases to the debaters**
- 16.15 – 16.45 **Clinical cases: Partial nephrectomy: Targeting the best approach for the best patients**  
Chair: P. Gontero, Turin (IT)
- Panelists: A. Minervini, Florence (IT)  
P. Mulders, Nijmegen (NL)  
J. Pena, Barcelona (ES)  
H. Van Poppel, Leuven (BE)  
A. Volpe, Novara (IT)
- 16.45 – 17.00 **Refreshment break**
- 17.00 – 17.45 **DEBATE: Alternative treatments of small renal masses in the elderly ( $\geq 75$  years) with co-morbid conditions**  
Chairs: A. Govorov, Moscow (RU)  
A. Volpe, Novara (IT)
- 17.00 – 17.10 **Focal therapy (Video)**  
P. Laguna, Amsterdam (NL)
- 17.10 – 17.30 **Surgery (minimally invasive: R/LAP) (Video)**  
F. Gaboardi, Milan (IT)  
A. Mottrie, Aalst (BE)
- 17.30 – 17.40 **Mini-Open: Still room? (Video)**  
M. Brausi, Modena (IT)
- 17.40 – 17.45 **Discussion**

- 17.45 – 18.45**    **Urothelial and bladder cancer I**  
Chairs: W. Artibani, Verona (IT)  
          G. Thalmann, Berne (CH)
- 17.45 – 17.55**    **Recovery enhancement programmes for radical cystectomy**  
M. Colombel, Lyon (FR)
- 17.55 – 18.05**    **How to prevent and reduce the complication rate in patients eligible for radical cystectomy?**  
M. Rink, Hamburg (DE)
- 18.05 – 18.10**    **Discussion**
- 18.10 – 18.45**    **DEBATE: Radical cystectomy vs bladder sparing modalities in the elderly ( $\geq 75$  years)**
- 18.10 – 18.20**    **Radical cystectomy**  
A. Stenzl, Tübingen (DE)
- 18.20 – 18.30**    **Bladder sparing modalities**  
R. Huddart, Sutton (GB)
- 18.30 – 18.45**    **Questions to debaters and clinical cases**  
W. Artibani, Verona (IT)

## Saturday, 21 January 2017

- 08.30 – 10.30 Prostate cancer II: Diagnosis and locally advanced**  
Chairs: N. Clarke, Manchester (GB)  
F. Montorsi, Milan (IT)
- 08.30 – 08.45 Ideal anatomical extent of lymphadenectomy**  
P. Sooriakumaran, London (GB)
- 08.45 – 09.00 Novel diagnostic tools for lymph node staging**  
M. Graefen, Hamburg (DE)
- 09.00 – 09.55 Extended lymphadenectomy in high risk prostate cancer: Different approaches**
- 09.00 – 09.15 Open approach (Video)**  
S. Joniau, Leuven (BE)
- 09.15 – 09.30 Laparoscopic approach (Video)**  
J. Rassweiler, Heilbronn (DE)
- 09.30 – 09.45 Robotic approach (Video)**  
H. Van Der Poel, Amsterdam (NL)
- 09.45 – 09.55 Discussion**
- 09.55 – 10.10 Pathological evaluation of lymph nodes: What urologists should know from pathologists and vice versa**  
F. Algaba, Barcelona (ES)
- 10.10 – 10.15 Discussion**
- 10.15 – 10.25 Adjuvant treatment in node positive patients with undetectable PSA**  
N. Clarke, Manchester (GB)
- 10.25 – 10.30 Discussion**
- 10.30 – 11.30 Testis and penile cancer**  
Chairs: P. Chlosta, Cracow (PL)  
J. Rubio, Valencia (ES)
- 10.30 – 10.45 How to avoid sub-optimal treatment outcomes in testicular cancer**  
A. Heidenreich, Cologne (DE)
- 10.45 – 10.50 Discussion**
- 10.50 – 11.05 Lymph node staging in penile cancer: When and how**  
C. Protzel, Rostock (DE)
- 11.05 – 11.20 Robotic inguinal lymph node dissection in penile cancer**  
V. Sangar, Manchester (GB)
- 11.20 – 11.30 Discussion**
- 11.30 – 12.00 Refreshment break**

- 12.00 – 13.45 Urothelial cancer II: Challenges in muscle invasive and non-muscle invasive bladder cancer**  
 Chairs: M. Colombel, Lyon (FR)  
 J. Palou, Barcelona (ES)
- 12.00 – 12.15 Unusual metastatic sites after minimally invasive radical cystectomy: Myth or reality?**  
 R. Van Velthoven, Brussels (BE)
- 12.15 – 12.20 Discussion**
- 12.20 – 12.35 Salvage radical cystectomy after radiotherapy: A more complicated procedure?**  
 P. Gontero, Turin (IT)
- 12.35 – 12.40 Discussion**
- 12.40 – 13.00 DEBATE: BCG as the standard treatment of T1 HG TCC of the bladder: Still true?**
- 12.40 – 12.50 Yes**  
 M. Babjuk, Prague (CZ)
- 12.50 – 13.00 No**  
 M. Brausi, Modena (IT)
- 13.00 – 13.30 Challenges in NMIBC: Case presentation**
- Chair: J. Palou, Barcelona (ES)
- Panelists: M. Babjuk, Prague (CZ)  
 M. Brausi, Modena (IT)  
 A. Masson-Lecomte, Creteil (FR)  
 M. Oderda, Turin (IT)  
 E. Xylinas, Paris (FR)
- 13.30 – 13.45 Up-date in the diagnosis and treatment of upper urinary tract transitional cell carcinoma (UUT TCC)**  
 M. Rouprêt, Paris (FR)
- 14.30 – 16.45 STEPS (Session To Evaluate ProgresS) programme**  
**Closed programme: participation by invitation only**

Led by Prof. M. Brausi, Modena (IT)

Prostate Cancer table: Chair: C. Evans, Sacramento (US)	ESOU: S. Joniau, Leuven (BE)
Bladder Cancer table: Chair: R. Hautmann, Neu-Ulm (DE)	ESOU: M. Colombel, Lyon (FR)
Renal Cancer table: Chair: P. Mulders, Nijmegen (NL)	ESOU: P. Chlosta, Cracow (PL)
Testis Cancer table: Chair: A. Heidenreich, Cologne (DE)	ESOU: M. Sedelaar, Nijmegen (NL)

**14.30 – 17.30 ESU Course on Complications and management of patients undergoing cystectomy**

Chair: J. Palou, Barcelona (ES)

Faculty: N. Clarke, Manchester (GB)

J.M. Gaya, Barcelona (ES)

G. Thalmann, Berne (CH)

Radical cystectomy is one of the most complicated surgeries in urology. The correct management at all the different steps is the key for success and to avoid or at least decrease postoperative complications. We will review the different steps and main problems to deal with when deciding, doing or controlling a patient after cystectomy. We will focus on practical aspects that will help urologists and their patients that have to undergo this radical surgery.

**14.30 European School of Urology: a unique possibility for urological education**

**14.35 Open discussion on Preoperative priorities**

- *Nutrition preop*
- *Bowel preparation*
- *Anemia*
- *Location of the stoma*
- *Renal function*
- *Medication including prophylaxis*

Chair and faculty

**15.25 Intraoperative**

- *Rectal injury*
- *Vascular injury*
- *Urethral margin*
- *Ureteral margins*
- *Nerve sparing*
- *Stenting?*
- *Which diversion and when*

Chair and faculty

**16.15 Refreshment break**

**16.35 Postoperative**

- *Fever*
- *Ileus: basic steps*
- *Urine leak*
- *Bowel leak*
- *Wound dehiscence*
- *When to remove stents*
- *Antibiotics*

*Follow-up of the incontinent diversion*

*Follow-up of the neobladder*

Chair and faculty

**17.30 Close**

# Sunday, 22 January 2017

## 09.00 – 10.00 Renal cancer II: Locally advanced and metastatic

Chairs: M. De Santis, Coventry (GB)  
H. Van Poppel, Leuven (BE)

09.00 – 09.15 Cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era

O. Rodriguez Faba, Barcelona (ES)

09.15 – 09.20 Discussion

09.20 – 09.35 Disasters in renal cancer surgery: How to avoid them (Video)

V. Pansadoro, Rome (IT)

09.35 – 09.40 Discussion

09.40 – 09.55 The role of medical treatment of locally advanced renal cancer

P. Mulders, Nijmegen (NL)

09.55 – 10.00 Discussion

## 10.00 – 11.10 The best of uro-oncology in 2016

Chairs: V. Ficarra, Udine (IT)  
M. Sedelaar, Nijmegen (NL)

10.00 – 10.15 Kidney cancer

U. Capitanio, Milan (IT)

10.15 – 10.30 Bladder cancer

A. Noon, Sheffield (GB)

10.30 – 10.45 Testis cancer

M. Salagierski, Zielona Góra (PL)

10.45 – 11.00 Prostate cancer

R. Van Den Bergh, Amsterdam (NL)

11.00 – 11.10 Discussion

## 11.10 – 11.30 Refreshment break

## 11.30 – 12.50 Prostate and bladder cancer III: Advanced and metastatic

Chairs: B. Djavan, Vienna (AT)  
C. Evans, Sacramento (US)

11.30 – 11.45 Checkpoint inhibitors in bladder cancer

G. Thalmann, Berne (CH)

11.45 – 11.50 Discussion

11.50 – 12.05 Robotic salvage retroperitoneal lymph node dissection for patients with an elevated PSA after radical prostatectomy (Video)

F. Montorsi, Milan (IT)

12.05 – 12.10 Discussion



- 12.10 - 12.25 **Radical prostatectomy in oligo metastatic disease (Video)**  
S. Joniau, Leuven (BE)
- 12.25 - 12.30 Discussion
- 12.30 - 12.45 **Which men with primary metastatic prostate cancer should have cytotoxic agents upfront?**  
M. De Santis, Coventry (GB)
- 12.45 - 12.50 Discussion
- 12.50 - 13.00 **Announcement of ESOU Achievement Award**
- 13.00 - 13.10 **Closing remarks**  
M. Brausi, Modena (IT)  
P. Gontero, Turin (IT)  
J. Palou, Barcelona (ES)